iTeos Therapeutics (ITOS) said Monday that it has agreed to be acquired by Concentra Biosciences for $10.047 per share in cash and a contingent value right.
The iTeos board of directors has unanimously determined that the acquisition by Concentra is in the best interests of all iTeos stockholders, it said.
Concentra will commence a tender offer by Aug. 1 to acquire all iTeos' outstanding shares, and the deal is expected to close by Q3, the company said.
The offer will close only if a majority of iTeos shares are tendered, including those already held by Concentra and its affiliates, at least $475 million in cash is available at closing, and other standard conditions are met, iTeos said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.